Journal
Therapeutic Advances in Infectious Disease
Publication Date
4-22-2025
Volume
12
First Page
20499361251333617
Document Type
Open Access Publication
DOI
10.1177/20499361251333617
Rights and Permissions
Mena Lora AJ, Enders K, Wu H, Parra-Rodriguez L, Palma C, Saliba K, Laverdurre S, Smith PB, Anstrom KJ, Bozzette SA, Powderly WG. SARS-CoV-2 N protein and anti-spike serologies: insights into COVID-19 disease severity and mortality-a secondary analysis of the ACTIV-1 trial. Ther Adv Infect Dis. 2025 Apr 22;12:20499361251333617. doi: 10.1177/20499361251333617. © The Author(s), 2025. Creative Commons License (CC BY-NC 4.0) This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
Recommended Citation
Mena Lora, Alfredo J; Enders, Kimi; Wu, Huimin; Parra-Rodriguez, Luis; Palma, Christopher; Saliba, Katy; Laverdurre, Sylvain; Smith, P Brian; Anstrom, Kevin J; Bozzette, Samuel A; and Powderly, William G, "SARS-CoV-2 N protein and anti-spike serologies: Insights into COVID-19 disease severity and mortality-a secondary analysis of the ACTIV-1 trial." Therapeutic Advances in Infectious Disease. 12, 20499361251333617 (2025).
https://digitalcommons.wustl.edu/oa_4/5434
Department
ICTS (Institute of Clinical and Translational Sciences)
Additional Links
Supplemental material is available for this article at publisher site.
